TickerFacts.

Immucell Corp (ICCC): Shareholders' Equity

Annual figures by period end, from SEC filings.

$27.06M
As of 2025-12-31
$31.37M
As of 2026-06-30
-3.8%
3-year compound annual growth
-0.9%
5-year compound annual growth
+9.8%
10-year compound annual growth
$32.58M2009-12-31: $9.62M2010-12-31: $9.28M2011-12-31: $9.02M2012-12-31: $9.19M2013-12-31: $9.40M2014-12-31: $9.26M2015-12-31: $10.61M2016-12-31: $19.72M2017-12-31: $23.59M2018-12-31: $21.74M2019-12-31: $28.99M2020-12-31: $28.27M2021-12-31: $32.58M2022-12-31: $30.38M2023-12-31: $24.99M2024-12-31: $27.52M2025-12-31: $27.06M$27.06M
2009-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$27.06M-1.7%2026-03-30, Balance as of period end
2024-12-31$27.52M+10.1%2026-03-30, Balance as of period end
2023-12-31$24.99M-17.7%2025-03-28, Balance as of period end
2022-12-31$30.38M-6.7%2024-04-01, Balance as of period end
2021-12-31$32.58M+15.3%2023-03-29, Balance as of period end
2020-12-31$28.27M-2.5%2022-03-30, Balance as of period end
2019-12-31$28.99M+33.3%2021-03-30, Balance as of period end
2018-12-31$21.74M-7.8%2020-03-27, Balance as of period end
2017-12-31$23.59M+19.6%2019-03-22, Balance as of period end
2016-12-31$19.72M+85.8%2018-03-29, Balance as of period end
2015-12-31$10.61M+14.6%2017-03-30, Balance as of period end
2014-12-31$9.26M-1.5%2016-03-25, Balance as of period end
2013-12-31$9.40M+2.2%2016-03-25, Balance as of period end
2012-12-31$9.19M+1.9%2015-03-26, Balance as of period end
2011-12-31$9.02M-2.8%2014-03-26, Balance as of period end
2010-12-31$9.28M-3.5%2013-03-28, Balance as of period end
2009-12-31$9.62Mn/a2012-03-27, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Immucell Corp (ICCC)2025-12-31$27.06M-1.7%
Alpha Teknova, Inc. (TKNO)2025-12-31$68.78M-16.5%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$671.39M-23.0%
Aspira Women's Health Inc. (AWHL)2025-12-31-$6.93Mn/m
Anbio Biotechnology (NNNN)2025-12-31$30.16M+75.4%
Biomerica Inc (BMRA)2026-05-31$2.63M-35.9%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$31.46Mn/m
Volitionrx Ltd (VNRX)2025-12-31-$34.25Mn/m
Celldex Therapeutics, Inc. (CLDX)2025-12-31$527.16M-29.4%

Compare ICCC, TKNO, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗